Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) for the treatment of HIV

The fixed-dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate is taken once a day in tablet form. One tablet contains 100 mg of doravirine, 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate.

The first-line treatments for HIV-1 in adults are the drugs rilpivirine or dolutegravir, which are each used in combination with two other drugs such as tenofovir alafenamide and emtricitabine or abacavir and lamivudine. Instead of tenofovir alafenamide, the drug tenofovir disoproxil is also an option.

Adults who have already taken medication for HIV are generally given individually tailored combination therapy for HIV. This type of treatment takes into consideration which treatments were tried before and why they were stopped. For instance, the previous treatment may have been ineffective or caused side effects that were too severe.

In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether the fixed-dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate has any advantages or disadvantages in the treatment of HIV-1 infection in adults compared with the standard treatments.
The manufacturer only provided data to make an indirect comparison.

In scientific research, a direct comparison is a comparison made between two medications in a single study. Half of the participants in the study are given medication A, and the other half receive the standard treatment. After the study is completed, the numbers of certain events in each group – such as deaths, occurrences of symptoms or side effects – are compared.

Indirect comparisons, on the other hand, involve two different studies (in the simplest case): One study compares medication A with medication X. The other compares medication X with the standard treatment. Then the results for medication A from the first study are compared with the results for the standard treatment from the second study. The results of this kind of comparison are generally less reliable than a direct comparison.

In this case, one study compared the fixed-dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate with efavirenz, emtricitabine and tenofovir disoproxil fumarate. Two other studies compared efavirenz, emtricitabine and tenofovir disoproxil fumarate with the standard treatment of dolutegravir and two additional drugs.

The indirect comparison showed the following results in people who have not yet taken any other medication to treat HIV:

What are the advantages and disadvantages of the fixed-dose combination?

The indirect comparison showed no advantages or disadvantages of doravirine, lamivudine and tenofovir disoproxil fumarate in comparison to the standard treatment of dolutegravir and two additional drugs.

No difference

• Number of AIDS-related illnesses: Various bacterial, viral and fungal infections are more likely if the immune system is weakened due to HIV. Some types of tumors are also more common. The success of a particular treatment can be measured by whether these illnesses are less common in people who have the treatment. There was no difference between the treatments in the indirect comparison.
• No difference was found in terms of the following, either:
  • Life expectancy
  • Serious side effects
  • Treatment stopped due to side effects

What remains unanswered?

Quality of life: The studies didn't look into quality of life.

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of the fixed-dose combination of doravirine, lamivudine and tenofovir disoproxil fumarate (Delstrigo).